Last reviewed · How we verify
Docetaxel, Doxorubicin, Cyclophosphamide
Docetaxel, Doxorubicin, Cyclophosphamide is a Chemotherapy combination (taxane + anthracycline + alkylating agent) Small molecule drug developed by Peking Union Medical College Hospital. It is currently in Phase 3 development for Breast cancer (neoadjuvant and adjuvant treatment), Locally advanced or metastatic breast cancer.
This combination chemotherapy regimen kills cancer cells by damaging DNA and disrupting cell division through multiple mechanisms: docetaxel stabilizes microtubules, doxorubicin intercalates DNA, and cyclophosphamide alkylates DNA.
This combination chemotherapy regimen kills cancer cells by damaging DNA and disrupting cell division through multiple mechanisms: docetaxel stabilizes microtubules, doxorubicin intercalates DNA, and cyclophosphamide alkylates DNA. Used for Breast cancer (neoadjuvant and adjuvant treatment), Locally advanced or metastatic breast cancer.
At a glance
| Generic name | Docetaxel, Doxorubicin, Cyclophosphamide |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Chemotherapy combination (taxane + anthracycline + alkylating agent) |
| Target | Microtubules (docetaxel), DNA (doxorubicin and cyclophosphamide) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel is a taxane that prevents microtubule depolymerization, halting mitosis. Doxorubicin is an anthracycline that intercalates into DNA and generates reactive oxygen species, causing strand breaks. Cyclophosphamide is an alkylating agent that cross-links DNA strands. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Breast cancer (neoadjuvant and adjuvant treatment)
- Locally advanced or metastatic breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Mucositis
- Peripheral neuropathy
- Cardiotoxicity
- Fatigue
Key clinical trials
- Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (PHASE2)
- Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (PHASE2)
- Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer (NA)
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
- Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer (PHASE2)
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy (PHASE2)
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel, Doxorubicin, Cyclophosphamide CI brief — competitive landscape report
- Docetaxel, Doxorubicin, Cyclophosphamide updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI
Frequently asked questions about Docetaxel, Doxorubicin, Cyclophosphamide
What is Docetaxel, Doxorubicin, Cyclophosphamide?
How does Docetaxel, Doxorubicin, Cyclophosphamide work?
What is Docetaxel, Doxorubicin, Cyclophosphamide used for?
Who makes Docetaxel, Doxorubicin, Cyclophosphamide?
What drug class is Docetaxel, Doxorubicin, Cyclophosphamide in?
What development phase is Docetaxel, Doxorubicin, Cyclophosphamide in?
What are the side effects of Docetaxel, Doxorubicin, Cyclophosphamide?
What does Docetaxel, Doxorubicin, Cyclophosphamide target?
Related
- Drug class: All Chemotherapy combination (taxane + anthracycline + alkylating agent) drugs
- Target: All drugs targeting Microtubules (docetaxel), DNA (doxorubicin and cyclophosphamide)
- Manufacturer: Peking Union Medical College Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer (neoadjuvant and adjuvant treatment)
- Indication: Drugs for Locally advanced or metastatic breast cancer
- Compare: Docetaxel, Doxorubicin, Cyclophosphamide vs similar drugs
- Pricing: Docetaxel, Doxorubicin, Cyclophosphamide cost, discount & access